ESSA Pharma (EPIX) said late Thursday it decided to terminate the phase 2 trial evaluating the combination of masofaniten and enzalutamide in patients with metastatic castration-resistant prostate cancer compared with enzalutamide alone.
Shares slumped 71%, with intraday trading volume at over 27.6 million compared with a daily average of about 59,000.
Lexicon Pharmaceuticals (LXRX) said late Thursday that the Endocrinologic and Metabolic Drugs Advisory Committee of the US Food and Drug Administration voted 11-3 against recommending Zynquista (sotagliflozin) as an add-on to insulin therapy for glycemic control in adults suffering from type 1 diabetes and chronic kidney disease.
Shares sank 37% as intraday trading volume catapulted to more than 16.8 million from a daily average of about 2.7 million.
Autonomix Medical (AMIX) unveiled Friday the launch of a public offering of up to 698,812 common stock units at $14.31 each.
Shares retreated 24%, with intraday trading volume at over 341,000 versus a daily average of roughly 451,000.
Price: 1.52, Change: -3.68, Percent Change: -70.77
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。